Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

A Novel Immunoproteasome Activator That Expands and Amplifies the Multiple Myeloma Immunopeptidome and Promotes Cytotoxic T-Cell Activity

James J. Driscoll, II, Ehsan Malek, Priyanka S. Rana, James J Ignatz-Hoover

Blood (2024) 144 (Supplement 1): 6832.

https://doi.org/10.1182/blood-2024-211485

Published: 2024

Journal Articles

Speeding up Myeloma Care: Robust Machine Learning Predictions of M-Spike Levels

Ehsan Malek, Juan Pablo Capdevila, Jennifer M. Ahlstrom, Jorge Arturo Hurtado Martinez, Gi-Ming Wang, Jay R. Hydren, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 7604.

https://doi.org/10.1182/blood-2024-200888

Published: 2024

Journal Articles

Machine Learning in Myeloma: Do Racial Differences Influences Systemic Impact of Multiple Myeloma?

Hector Tirado, Jorge Arturo Hurtado Martinez, Jennifer M. Ahlstrom, Jay R. Hydren, Juan Pablo Capdevila, James J. Driscoll, II, Gi-Ming Wang, Ehsan Malek

Blood (2024) 144 (Supplement 1): 7840.

https://doi.org/10.1182/blood-2024-208026

Published: 2024

Journal Articles

The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial

Ehsan Malek, James J Ignatz-Hoover, Priyanka S. Rana, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 7042.

https://doi.org/10.1182/blood-2024-211233

Published: 2024

Journal Articles

Real-World Evidence for Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients

Jeries Kort, James J Ignatz-Hoover, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 3773.

https://doi.org/10.1182/blood-2024-210334

Published: 2024

Journal Articles

PSMC2 Overexpression Promotes Synthetic Lethality Sensitizing Multiple Myeloma Cells to p97 Inhibition

James J Ignatz-Hoover, Pryianka Rana, John D'Cruz, E Ricky Chan, Ehsan Malek, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2024-211260

Published: 2024

Journal Articles

HDAC6 Inhibition Activates Proteasomes to Modulate the MHC Class I Immunopeptidome and Promote Antimyeloma Immunity

Priyanka S. Rana, James J. Ignatz-Hoover, Ehsan Malek, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 6586.

https://doi.org/10.1182/blood-2023-189262

Published: 2023

Journal Articles

An Immunoproteasome Activator That Increases MHC Class I Antigen Presentation to Enhance Anti-Tumor Immunity

James J. Driscoll, II, Priyanka S. Rana, Ehsan Malek, James J. Ignatz-Hoover

Blood (2023) 142 (Supplement 1): 3642.

https://doi.org/10.1182/blood-2023-189541

Published: 2023

Journal Articles

PSMC2 Overexpression Enhances Proteasome Activity, Mitigates ER Stress, and Correleates with Reduced Overall Survival in Multiple Myeloma

James J. Ignatz-Hoover, E Ricky Chan, Jack D'Cruz, Pryianka Rana, Ehsan Malek, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 6617.

https://doi.org/10.1182/blood-2023-190462

Published: 2023

Journal Articles

Leveraging Artificial Intelligence to Uncover Hidden Biases in Survival Disparities of Patients with Multiple Myeloma

Ehsan Malek, Rishi Chopra, James J. Driscoll, II, Pingfu Fu

Blood (2023) 142 (Supplement 1): 7409.

https://doi.org/10.1182/blood-2023-172712

Published: 2023

Journal Articles

Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma

Ehsan Malek, Priyanka S. Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J. Ignatz-Hoover, Leland Metheny, Seong-Jin Kim, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 4749.

https://doi.org/10.1182/blood-2023-172711

Published: 2023

Journal Articles

Toward AI-Assisted Clinical Assessment for Patients with Multiple Myeloma: Feature Selection for Large Language Models

Ehsan Malek, Gi-Ming Wang, Anant Madabhushi, Jennifer Cullen, Curtis Tatsuoka, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 2328.

https://doi.org/10.1182/blood-2023-172710

Published: 2023

Journal Articles

Utilizing a Machine Learning Approach to Define Racial Difference in Multi-Systemic Impact of Monoclonal Protein in Patient with Multiple Myeloma

Ehsan Malek, Gi-Ming Wang, Jennifer Cullen, Curtis Tatsuoka, Anant Madabhushi, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 7343.

https://doi.org/10.1182/blood-2023-172742

Published: 2023

Journal Articles

A Risk Model to Predict the Longitudinal Decline in Creatinine Clearance Among Patients with Precursor Plasma Cell Dyscrasia with Baseline Chronic Kidney Failure

Jeries Kort, Pingfu Fu, Leland Metheny, Ravi Kyasaram, James J. Driscoll, Ehsan Malek

Blood (2022) 140 (Supplement 1): 13176–13177.

https://doi.org/10.1182/blood-2022-162641

Published: 2022

Journal Articles

Proteasome Regulatory Atpases PSMC2 and PSMC6 Modulate Proteosome Inhibitor Sensitivity and Correlate with Survival in Multiple Myeloma

James Ignatz-Hoover, E Ricky Chan, Ehsan Malek, James J. Driscoll

Blood (2022) 140 (Supplement 1): 4305–4306.

https://doi.org/10.1182/blood-2022-170510

Published: 2022

Journal Articles

Artificial Intelligence to Assess the Systemic Impact of Malignant Plasma Cell Clone in Patients with Plasma Cell Dyscrasia

Ehsan Malek, Jeries Kort, Gi-Ming Wang, Curtis Tatsuoka, James J. Driscoll

Blood (2022) 140 (Supplement 1): 7856–7857.

https://doi.org/10.1182/blood-2022-159536

Published: 2022

Journal Articles

A Tool to Longitudinally Assess the Secretory Capacity of Myeloma Cells throughout the Course of Disease

Nicholas J. Donato, Hannah Elizabeth Schmikla, James J. Driscoll, Rishil Chopra, Ehsan Malek

Blood (2022) 140 (Supplement 1): 4979–4980.

https://doi.org/10.1182/blood-2022-162522

Published: 2022

Journal Articles

Early Onset of Smoldering Disease Correlates with Rapid Progression to Symptomatic Multiple Myeloma

Fahrettin Covut, Rishil Chopra, Sathya Sri Areti, James J. Driscoll, Ehsan Malek

Blood (2022) 140 (Supplement 1): 10816–10817.

https://doi.org/10.1182/blood-2022-163721

Published: 2022

Journal Articles

African American Race Is a Potential Favorable Biologic Factor That Impacts Clinical Outcome for Patients with Multiple Myeloma

Jeries Kort, Leland Metheny, Pingfu Fu, Shufen Cao, James J. Driscoll, Ehsan Malek

Blood (2022) 140 (Supplement 1): 7244–7245.

https://doi.org/10.1182/blood-2022-170717

Published: 2022

Journal Articles

Multidimensional Quantification of Exclusion Criteria to Reduce the Gap between Randomized Clinical Trial and Real-World Outcomes in Multiple Myeloma

Augusta Eduafo, Leland Metheny, III, Ravi Kyasaram, Farhad Sanati, James J. Driscoll, Ehsan Malek

Blood (2021) 138 (Supplement 1): 4003.

https://doi.org/10.1182/blood-2021-148222

Published: 2021

NARROW

A Novel Immunoproteasome Activator That Expands and Amplifies the Multiple Myeloma Immunopeptidome and Promotes Cytotoxic T-Cell Activity

Speeding up Myeloma Care: Robust Machine Learning Predictions of M-Spike Levels

Machine Learning in Myeloma: Do Racial Differences Influences Systemic Impact of Multiple Myeloma?

The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial

Real-World Evidence for Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients

PSMC2 Overexpression Promotes Synthetic Lethality Sensitizing Multiple Myeloma Cells to p97 Inhibition

HDAC6 Inhibition Activates Proteasomes to Modulate the MHC Class I Immunopeptidome and Promote Antimyeloma Immunity

An Immunoproteasome Activator That Increases MHC Class I Antigen Presentation to Enhance Anti-Tumor Immunity

PSMC2 Overexpression Enhances Proteasome Activity, Mitigates ER Stress, and Correleates with Reduced Overall Survival in Multiple Myeloma

Leveraging Artificial Intelligence to Uncover Hidden Biases in Survival Disparities of Patients with Multiple Myeloma

Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma

Toward AI-Assisted Clinical Assessment for Patients with Multiple Myeloma: Feature Selection for Large Language Models

Utilizing a Machine Learning Approach to Define Racial Difference in Multi-Systemic Impact of Monoclonal Protein in Patient with Multiple Myeloma

A Risk Model to Predict the Longitudinal Decline in Creatinine Clearance Among Patients with Precursor Plasma Cell Dyscrasia with Baseline Chronic Kidney Failure

Proteasome Regulatory Atpases PSMC2 and PSMC6 Modulate Proteosome Inhibitor Sensitivity and Correlate with Survival in Multiple Myeloma

Artificial Intelligence to Assess the Systemic Impact of Malignant Plasma Cell Clone in Patients with Plasma Cell Dyscrasia

A Tool to Longitudinally Assess the Secretory Capacity of Myeloma Cells throughout the Course of Disease

Early Onset of Smoldering Disease Correlates with Rapid Progression to Symptomatic Multiple Myeloma

African American Race Is a Potential Favorable Biologic Factor That Impacts Clinical Outcome for Patients with Multiple Myeloma

Multidimensional Quantification of Exclusion Criteria to Reduce the Gap between Randomized Clinical Trial and Real-World Outcomes in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only